Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages

Journal of Controlled Release

Volumn 107, Issue 2, 2005, Pages 288-299

  Zhou, Huiyu ^a,e   Zhang, Yanling ^a   Biggs, Danielle L ^b   Manning, Mark C ^c   Randolph, Theodore W ^d   Christians, Uwe ^a   Hybertson, Brooks M ^a   Ng, Ka Yun ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c HTD Biosystems   (United States)

^d UCB 450   (United States)

^e 206 Carnegie Center   (United States)

Author keywords

Drug targeting; Isoniazid; Microparticle; Sustained release; Tuberculosis

Indexed keywords

DISEASES; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POSITIVE IONS; PRECIPITATION (CHEMICAL); REACTION KINETICS;

DRUG-TARGETING; ISONIAZID (INH); MICROPARTICLES; SUSTAINED-RELEASE; TUBERCULOSIS;

METABOLISM;

ACETYLISONIAZID; CATION; ISONIAZID; METHANIAZIDE; POLYLACTIDE; POLYMER; PRODRUG; TETRAHEPTYLAMMONIUM SALT; TETRAPENTYLAMMONIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG INSTILLATION; DRUG METABOLISM; DRUG RELEASE; DRUG SCREENING; DRUG TARGETING; HYDROPHOBICITY; IN VIVO STUDY; KINETICS; LIQUID CHROMATOGRAPHY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; TARGET CELL;

ANIMALS; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ISONIAZID; LUNG; MACROPHAGES, ALVEOLAR; MALE; MASS SPECTROMETRY; MICROSCOPY, ELECTRON, SCANNING; NANOSTRUCTURES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 24944524961     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.06.009     Document Type: Article

References (50)

1. Z. Toossi, and J. Ellner L.N. Friedman Tuberculosis: Current Concepts and Treatment 2nd edition 2001 CRC Press Boca Raton, Florida 19 48
2. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country World Health Organization Global Surveillance and Monitoring Project JAMA vol. 282 1999 677 686
3. T. Arnadottir Tuberculosis: trends and the twenty-first century Scand. J. Infect. Dis. 33 2001 563 567
4. W.W. Addington Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States Chest 76 1979 741 743
5. T. Schaberg The dark side of antituberculosis therapy: adverse events involving liver function Eur. Respir. J. 8 1995 1247 1249
6. P.T. Davidson, and H.Q. Le Drug treatment of tuberculosis-1992 Drugs 43 1992 651 673
7. World Health Organization Report Global Tuberculosis Control- Surveillance, Planning, Financing 2004
8. S. Kailasam, D. Daneluzzi, and P.R. Gangadharam Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer Tuber. Lung Dis. 75 1994 361 365
9. P.R. Gangadharam, N. Geeta, Y.Y. Hsu, and D.L. Wise Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide Int. J. Tuberc. Lung Dis. 3 1999 515 520
10. P. O'Hara, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharm. Res. 17 2000 955 961
11. M. Dutt, and G.K. Khuller Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis Int. J. Antimicrob. Agents 17 2001 115 122
12. M. Dutt, and G.K. Khuller Liposomes and PLG microparticles as sustained release antitubercular drug carriers-an in vitro-in vivo study Int. J. Antimicrob. Agents 18 2001 245 252
13. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986
14. K. Makino, T. Nakajima, M. Shikamura, F. Ito, S. Ando, C. Kochi, H. Inagawa, G. Soma, and H. Terada Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin Colloids Surf., B Biointerfaces 36 2004 35 42
15. F. Ito, and K. Makino Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres Colloids Surf., B Biointerfaces 39 2004 17 21
16. E.L. Barrow, G.A. Winchester, J.K. Staas, D.C. Quenelle, and W.W. Barrow Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages Antimicrob. Agents Chemother. 42 1998 2682 2689
17. Y.V. Anisimova, S.I. Gelperina, C.A. Peloquin, and L.B. Heifets Nanoparticles as antituberculosis drugs carriers: effect on activity against mycobacterium tuberculosis in human moncyte-derived macrophages J. Nanopart. Res. 2 2000 165 171
18. M. Dutt, and G.K. Khuller Therapeutic efficacy of Poly(dl-lactide-Co- Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice Antimicrob. Agents Chemother. 45 2001 363 366
19. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410
20. F. Ahsan, I.P. Rivas, M.A. Khan, and A.I. Torres Suarez Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages J. Contemp. Relig. 79 2002 29 40
21. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Airways delivery of rifampicin microparticles for the treatment of tuberculosis J. Antimicrob. Chemother. 48 2001 431 434
22. H. Zhou, C. Lengsfeld, D.J. Claffey, J.A. Ruth, B. Hybertson, T.W. Randolph, K.Y. Ng, and M.C. Manning Hydrophobic ion pairing of isoniazid using a prodrug approach J. Pharm. Sci. 91 2002 1502 1511
23. J.A. Timbrell, J.R. Mitchell, W.R. Snodgrass, and S.D. Nelson Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo J. Pharmacol. Exp. Ther. 213 1980 364 369
24. H.H. Fox, and J. Gibas Synthetic tuberculostats: VIII. Acyl derivatives of isonicotinyl hydrazin J. Org. Chem. 18 1953 1375 1377
25. R.J. Helmke, R.L. Boyd, V.F. German, and J.A. Mangos From growth factor dependence to growth factor responsiveness: the genesis of an alveolar macrophage cell line In Vitro Cell Dev. Biol. 23 1987 567 574
26. K.Y. Ng, K.A. Stringer, Z. Cohen, R. Serravo, B. Tian, J.D. Meyer, R. Falk, T. Randolph, M.C. Manning, and D.C. Thompson Alveolar macrophage cell line is not activated by exposure to polymeric microspheres Int. J. Pharm. 170 1998 41 49
27. D.L. Biggs, C.S. Lengsfeld, B.M. Hybertson, K.Y. Ng, M.C. Manning, and T.W. Randolph In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response J. Contemp. Relig. 92 2003 147 161
28. R.F. Falk, T.W. Randolph, J.D. Meyer, R.M. Kelly, and M.C. Manning Controlled release of ionic compounds from poly (l-lactide) microspheres produced by precipitation with a compressed antisolvent J. Contemp. Relig. 44 1997 77 85
29. K.Y. Hsu, and Y. Ho Determination of isoniazid methanesulphonate and its metabolites in rabbit blood by high-performance liquid chromatography J. Chromatogr. 493 1989 305 312
30. M.A. Moulin, F. Albessard, J. Lacotte, and R. Camsonne Hydrophilic ion-pair reversed-phase high-performance liquid chromatography for the simultaneous assay of isoniazid and acetylisoniazid in serum: a microscale procedure J. Chromatogr. 226 1981 250 254
31. L.A. Moussa, C.E. Khassouani, R. Soulaymani, M. Jana, G. Cassanas, R. Alric, and B. Hue Therapeutic isoniazid monitoring using a simple high-performance liquid chromatographic method with ultraviolet detection J. Chromatogr., B Anal. Technol. Biomed. Life Sci. 766 2002 181 187
32. S.H. Gavett, D.J. O'Hearn, X. Li, S.K. Huang, F.D. Finkelman, and M. Wills-Karp Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice J. Exp. Med. 182 1995 1527 1536
33. CDER (2001). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine (CVM). Guidance for the Industry. Bioanalytical Method Validation, May 2001. www.fda.gov/cder/guidance.
34. K.C. Stone, R.R. Mercer, P. Gehr, B. Stockstill, and J.D. Crapo Allometric relationships of cell numbers and size in the mammalian lung Am. J. Respir. Cell Mol. Biol. 6 1992 235 243
35. B.E. Lehnert, Y.E. Valdez, and G.L. Tietjen Alveolar macrophage-particle relationships during lung clearance Am. J. Respir. Cell Mol. Biol. 1 1989 145 154
36. R. Falk, Gas Antisolvent Precipitation Processing for Preparation of Controlled-Release Pharmaceutical Products, Ph.D. Thesis. University of Colorado, Boulder, 1998.
37. D.J. Jarmer, C.S. Lengsfeld, and T.W. Randolph Manipulation of particle size distribution of poly(l-lactic acid) nanoparticles with a jet-swirl nozzle during precipitation with a compressed antisolvent J. Supercrit. Fluids 27 2003 317 336
38. Antituberculosis regimens of chemotherapy Recommendations from the committee on treatment of the international union against tuberculosis and lung disease Bull. Int. Union Against Tuberc. Lung Dis. 63 1988 60 64
39. J.L. Cleland, A. Daugherty, and R. Mrsny Emerging protein delivery methods Curr. Opin. Biotechnol. 12 2001 212 219
40. D.P. Speert, in C.E. Lewis, J.O'D. McGee (Eds.), The Natural Immune System: The Macrophage. Oxford University Press, New York, pp. 215-263.
41. E.F. Clarkson Tuberculosis. An overview J. Intraven. Nurs. 22 1999 216 220
42. R. Bodmeier, H. Wang, D.J. Dixon, S. Mawson, and K.P. Johnston Polymeric microspheres prepared by spraying into compressed carbon dioxide Pharm. Res. 12 1995 1211 1217
43. T.W. Randolph, A.D. Randolph, M. Mebes, and S. Yeung Sub-micrometer-sized biodegradable particles of poly(l-lactic acid) via the gas antisolvent spray precipitation process Biotechnol. Prog. 9 1993 429 435
44. Y.S. Cheng, D. Yazzie, J. Gao, D. Muggli, J. Etter, and G.J. Rosenthal Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology J. Aerosol Med. 16 2003 65 73
45. R.F. Falk, and T.W. Randolph Process variable implications for residual solvent removal and polymer morphology in the formation of gentamycin-loaded poly (l-lactide) microparticles Pharm. Res. 15 1998 1233 1237
46. C.J. van Oss Phagocytosis as a surface phenomenon Annu. Rev. Microbiol. 32 1978 19 39
47. K.E. Magnusson, O. Stendahl, I. Stjernstrom, and L. Edebo Reduction of phagocytosis, surface hydrophobicity and charge of Salmonella typhimurium 395 MR10 by reaction with secretory IgA (SIgA) Immunology 36 1979 439 447
48. E.L. Pesanti Role of surface wettability in phagocytosis of Neurospora crassa spores J. Reticuloendothel. Soc. 26 1979 549 552
49. T.R. Kozel, E. Reiss, and R. Cherniak Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide Infect. Immun. 29 1980 295 300
50. H. Kawaguchi, N. Koiwai, Y. Ohtsuka, M. Miyamoto, and S. Sasakawa Phagocytosis of latex particles by leucocytes: I. Dependence of phagocytosis on the size and surface potential of particles Biomaterials 7 1986 61 66